A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

All types of lung cancer develop more often in people who mine uranium, but small-cell lung cancer is most common. The prevalence goes up even more in uranium miners who smoke.

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

Data from the DeLLphi-304 trial “clearly support tarlatamab as a preferable therapy” for SCLC in the second-line setting, said Charles M. Rudin, MD, PhD.

Nine small health issues that might be an early sign of lung cancer - As the NHS offers ‘revolutionary’ blood test, here are ...

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more than 80% of lung cancer cases.

An international study, significantly shaped by Greek oncology, has unveiled a promising new treatment for small cell lung cancer (SCLC).

Imdelltra received accelerated approval from the U.S. Food and Drug Administration in May 2024 for patients with extensive-stage small cell lung cancer with disease progression on or after ...

The FDA has granted accelerated approval to datopotamab deruxtecan (Datroway) for adults with locally advanced or metastatic non-small cell lung cancer that carries an EGFR mutation and has progressed ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer.

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.